Business Description

Agilent Technologies Inc
NAICS : 334516
SIC : 3825
ISIN : US00846U1016
Description
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab (consisting of consumables and services related to life science and applied tools), and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. and China representing the largest country concentrations.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.61 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.5 | |||||
Debt-to-EBITDA | 1.56 | |||||
Interest Coverage | 17.3 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 5.83 | |||||
Beneish M-Score | -2.76 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.5 | |||||
3-Year EBITDA Growth Rate | 13.5 | |||||
3-Year EPS without NRI Growth Rate | 33.2 | |||||
3-Year FCF Growth Rate | 24.7 | |||||
3-Year Book Growth Rate | 7.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 4.82 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 2.34 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 26.46 | |||||
9-Day RSI | 27.76 | |||||
14-Day RSI | 32.64 | |||||
6-1 Month Momentum % | 7.49 | |||||
12-1 Month Momentum % | 44.07 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.78 | |||||
Quick Ratio | 1.37 | |||||
Cash Ratio | 0.74 | |||||
Days Inventory | 125.99 | |||||
Days Sales Outstanding | 66.46 | |||||
Days Payable | 57.06 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.72 | |||||
Dividend Payout Ratio | 0.18 | |||||
3-Year Dividend Growth Rate | 7.7 | |||||
Forward Dividend Yield % | 0.72 | |||||
5-Year Yield-on-Cost % | 1.09 | |||||
3-Year Average Share Buyback Ratio | 1.5 | |||||
Shareholder Yield % | 3.41 |
Profitability Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 54.39 | |||||
Operating Margin % | 22.9 | |||||
Net Margin % | 21.75 | |||||
FCF Margin % | 21.81 | |||||
ROE % | 23.78 | |||||
ROA % | 13.03 | |||||
ROIC % | 16.15 | |||||
3-Year ROIIC % | 58.71 | |||||
ROC (Joel Greenblatt) % | 74.15 | |||||
ROCE % | 18.1 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 27.23 | |||||
Forward PE Ratio | 23.2 | |||||
PE Ratio without NRI | 25.19 | |||||
Shiller PE Ratio | 42.33 | |||||
Price-to-Owner-Earnings | 27.08 | |||||
PEG Ratio | 2.1 | |||||
PS Ratio | 5.92 | |||||
PB Ratio | 6.39 | |||||
Price-to-Tangible-Book | 24.39 | |||||
Price-to-Free-Cash-Flow | 27.09 | |||||
Price-to-Operating-Cash-Flow | 21.53 | |||||
EV-to-EBIT | 23.95 | |||||
EV-to-Forward-EBIT | 23.37 | |||||
EV-to-EBITDA | 20.76 | |||||
EV-to-Forward-EBITDA | 20.43 | |||||
EV-to-Revenue | 5.99 | |||||
EV-to-Forward-Revenue | 5.7 | |||||
EV-to-FCF | 27.49 | |||||
Price-to-Projected-FCF | 2.02 | |||||
Price-to-DCF (Earnings Based) | 0.81 | |||||
Price-to-DCF (FCF Based) | 1.69 | |||||
Price-to-Median-PS-Value | 1.17 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.95 | |||||
Price-to-Graham-Number | 5.23 | |||||
Earnings Yield (Greenblatt) % | 4.18 | |||||
FCF Yield % | 3.76 | |||||
Forward Rate of Return (Yacktman) % | 15.85 |